- Home
- SACH vs MAIA Comparison
SACH vs MAIA Comparison
Compare SACH & MAIA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | SACH | MAIA |
|---|---|---|
| Founded | 2010 | 2018 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Real Estate Investment Trusts | Biotechnology: Pharmaceutical Preparations |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 52.0M | 44.9M |
| IPO Year | 2017 | 2022 |
Fundamental Metrics
Financial Performance| Metric | SACH | MAIA |
|---|---|---|
| Price | $1.12 | $1.20 |
| Analyst Decision | Hold | |
| Analyst Count | 3 | 0 |
| Target Price | ★ $2.00 | N/A |
| AVG Volume (30 Days) | 181.0K | ★ 454.0K |
| Earning Date | 11-05-2025 | 11-07-2025 |
| Dividend Yield | ★ 18.35% | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $3,906,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $1.73 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.80 | $0.87 |
| 52 Week High | $1.48 | $2.74 |
Technical Indicators
Market Signals| Indicator | SACH | MAIA |
|---|---|---|
| Relative Strength Index (RSI) | 57.96 | 53.94 |
| Support Level | $1.00 | $1.07 |
| Resistance Level | $1.08 | $1.25 |
| Average True Range (ATR) | 0.05 | 0.12 |
| MACD | 0.01 | 0.04 |
| Stochastic Oscillator | 72.22 | 55.93 |
Price Performance
Historical ComparisonAbout SACH Sachem Capital Corp.
Sachem Capital Corp is a real estate investment trust. The company specializes in originating, underwriting, funding, servicing, and managing a portfolio of short-term loans secured by first mortgage liens on real property located in Connecticut. Its primary objective is to grow the loan portfolio while protecting and preserving capital in a manner that provides for attractive risk-adjusted returns to shareholders over the long term through dividends. The company earns majority of its revenue through Interest income from loans.
About MAIA MAIA Biotechnology Inc.
MAIA Biotechnology Inc is a clinical-stage biopharmaceutical company developing targeted immunotherapies for cancer. THIO (6-thio-dG or 6-thio-2 '-deoxyguanosine), its lead asset, is an investigational dual mechanism of action drug candidate incorporating telomere targeting and immunogenicity. Patients with advanced NSCLC will be treated first with THIO followed a few days later by the immune checkpoint inhibitor Libtayo (cemiplimab), manufactured and commercialized by Regeneron.